$2.90
0.061.93%
Last update: Jul 17, 7:05 AM
15 minutes delayed
Comments
Loading...
SAB Biotherapeutics
SABSNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
SAB Biotherapeutics (NASDAQ:SABS) Stock, Analyst Ratings, Price Targets, Forecasts
SAB Biotherapeutics Inc has a consensus price target of $15.5 based on the ratings of 5 analysts. The high is $25 issued by Chardan Capital on May 21, 2024. The low is $6 issued by HC Wainwright & Co. on May 21, 2024. The 3 most-recent analyst ratings were released by Brookline Capital, HC Wainwright & Co., and Chardan Capital on June 7, 2024, May 21, 2024, and May 21, 2024, respectively. With an average price target of $13 between Brookline Capital, HC Wainwright & Co., and Chardan Capital, there's an implied 364.29% upside for SAB Biotherapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Brookline Capital
HC Wainwright & Co.
Chardan Capital
Baird
1calculated from analyst ratings
Analyst Ratings for SAB Biotherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/07/2024 | Buy Now | 185.71% | Brookline Capital | Kumaraguru Raja | → $8 | Initiates | → Buy | Get Alert |
| 05/21/2024 | Buy Now | 114.29% | HC Wainwright & Co. | Edward White | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/21/2024 | Buy Now | 792.86% | Chardan Capital | Keay Nakae | $25 → $25 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 114.29% | HC Wainwright & Co. | Edward White | → $6 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | 792.86% | Chardan Capital | Keay Nakae | $25 → $25 | Maintains | Buy | Get Alert |
| 04/02/2024 | Buy Now | 792.86% | Chardan Capital | Keay Nakae | $3 → $25 | Maintains | Buy | Get Alert |
| 04/02/2024 | Buy Now | 114.29% | HC Wainwright & Co. | Edward White | $10 → $6 | Maintains | Buy | Get Alert |
| 01/08/2024 | Buy Now | 257.14% | HC Wainwright & Co. | Edward White | $1 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2023 | Buy Now | -64.29% | HC Wainwright & Co. | Edward White | $20 → $10 | Maintains | Buy | Get Alert |
| 10/05/2023 | Buy Now | — | Ladenburg Thalmann | Jeffrey Cohen | — | Downgrade | Buy → Neutral | Get Alert |
| 08/21/2023 | Buy Now | -28.57% | HC Wainwright & Co. | Edward White | $40 → $20 | Maintains | Buy | Get Alert |
| 06/21/2023 | Buy Now | 42.86% | HC Wainwright & Co. | Edward White | → $40 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 42.86% | HC Wainwright & Co. | Edward White | → $40 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 7.14% | Chardan Capital | Keay Nakae | → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | Buy Now | 42.86% | HC Wainwright & Co. | Edward White | → $40 | Reiterates | Buy → Buy | Get Alert |
| 04/27/2023 | Buy Now | 7.14% | Chardan Capital | Keay Nakae | → $30 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 42.86% | HC Wainwright & Co. | Edward White | → $40 | Reiterates | → Buy | Get Alert |
| 04/03/2023 | Buy Now | 42.86% | HC Wainwright & Co. | Edward White | → $40 | Reiterates | → Buy | Get Alert |
| 11/29/2022 | Buy Now | 42.86% | HC Wainwright & Co. | Edward White | → $40 | Initiates | → Buy | Get Alert |
| 08/11/2022 | Buy Now | 7.14% | Chardan Capital | Keay Nakae | $70 → $30 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | 150% | Chardan Capital | Keay Nakae | $100 → $70 | Maintains | Buy | Get Alert |
| 04/01/2022 | Buy Now | 257.14% | Chardan Capital | Keay Nakae | $170 → $100 | Maintains | Buy | Get Alert |
| 11/05/2021 | Buy Now | 507.14% | Chardan Capital | Keay Nakae | → $170 | Initiates | → Buy | Get Alert |
| 11/02/2021 | Buy Now | 721.43% | Baird | Colleen Kusy | → $230 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for SAB Biotherapeutics (SABS) stock?
The latest price target for SAB Biotherapeutics (NASDAQ:SABS) was reported by Brookline Capital on June 7, 2024. The analyst firm set a price target for $8.00 expecting SABS to rise to within 12 months (a possible 175.86% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for SAB Biotherapeutics (SABS)?
The latest analyst rating for SAB Biotherapeutics (NASDAQ:SABS) was provided by Brookline Capital, and SAB Biotherapeutics initiated their buy rating.
When was the last upgrade for SAB Biotherapeutics (SABS)?
There is no last upgrade for SAB Biotherapeutics
When was the last downgrade for SAB Biotherapeutics (SABS)?
The last downgrade for SAB Biotherapeutics Inc happened on October 5, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for SAB Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on June 7, 2024 so you should expect the next rating to be made available sometime around June 7, 2025.
Is the Analyst Rating SAB Biotherapeutics (SABS) correct?
While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a initiated with a price target of $0.00 to $8.00. The current price SAB Biotherapeutics (SABS) is trading at is $2.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.